NCT04883905 ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
| NCT ID | NCT04883905 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alnylam Pharmaceuticals |
| Condition | Acute Hepatic Porphyria |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2021-04-26 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2021-04-26 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Eligibility Criteria
Inclusion Criteria: * Documented diagnosis of AHP, per physician's determination Exclusion Criteria: * Currently enrolled in a clinical trial for any investigational agent
Contact & Investigator
Medical Director
STUDY DIRECTOR
Alnylam Pharmaceuticals
Frequently Asked Questions
Who can join the NCT04883905 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Acute Hepatic Porphyria. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04883905 currently recruiting?
Yes, NCT04883905 is actively recruiting participants. Contact the research team at clinicaltrials@alnylam.com for enrollment information.
Where is the NCT04883905 trial being conducted?
This trial is being conducted at Birmingham, United States, Gilbert, United States, San Francisco, United States, Baltimore, United States and 11 additional locations.
Who is sponsoring the NCT04883905 clinical trial?
NCT04883905 is sponsored by Alnylam Pharmaceuticals. The principal investigator is Medical Director at Alnylam Pharmaceuticals. The trial plans to enroll 150 participants.